Zhaohui Feng

Dr. Zhaohui Feng


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
CZCen Zhang
Cen Zhang
JLJuan Liu
Juan Liu
YLYingjian Liang
Yingjian Liang
RWRui Wu
Rui Wu
YZYuhan Zhao
Yuhan Zhao
Zhaohui FengZhaohui Feng
Zhaohui Feng
Tumour cells primarily utilize aerobic glycolysis for energy production, a phenomenon known as the Warburg effect. Its mechanism is not well understood. The tumour suppressor gene p53 is frequently mutated in tumours. Many tumour-associated mutant p53 (mutp53) proteins not only lose tumour suppressive function but also gain new oncogenic functions that are independent of wild-type p53, defined as mutp53 gain of function (GOF). Here we show that tumour-associated mutp53 stimulates the Warburg effect in cultured cells and mutp53 knockin mice as a new mutp53 GOF. Mutp53 stimulates the Warburg effect through promoting GLUT1 translocation to the plasma membrane, which is mediated by activated RhoA and its downstream effector ROCK. Inhibition of RhoA/ROCK/GLUT1 signalling largely abolishes mutp53 GOF in stimulating the Warburg effect. Furthermore, inhibition of glycolysis in tumour cells greatly compromises mutp53 GOF in promoting tumorigenesis. Thus, our results reveal a new mutp53 GOF and a mechanism for controlling the Warburg effect.

28 July 2020 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
CZCen Zhang
Cen Zhang
JLJuan Liu
Juan Liu
DXDandan Xu
Dandan Xu
TZTianliang Zhang
Tianliang Zhang
WHWenwei Hu
Wenwei Hu
Zhaohui FengZhaohui Feng
Zhaohui Feng
P53 is a key tumor suppressor, and loss of p53 function is frequently a prerequisite for cancer development. The p53 gene is the most frequently mutated gene in human cancers; p53 mutations occur in >50% of all human cancers and in almost every type of human cancers. Most of p53 mutations in cancers are missense mutations, which produce the full-length mutant p53 (mutp53) protein with only one amino acid difference from wild-type p53 protein. In addition to loss of the tumor-suppressive function of wild-type p53, many mutp53 proteins acquire new oncogenic activities independently of wild-type p53 to promote cancer progression, termed gain-of-function (GOF). Mutp53 protein often accumulates to very high levels in cancer cells, which is critical for its GOF. Given the high mutation frequency of the p53 gene and the GOF activities of mutp53 in cancer, therapies targeting mutp53 have attracted great interest. Further understanding the mechanisms underlying mutp53 protein accumulation and GOF will help develop effective therapies treating human cancers containing mutp53. In this review, we summarize the recent advances in the studies on mutp53 regulation and GOF as well as therapies targeting mutp53 in human cancers.

30 November 2018 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
JLJuan Liu
Juan Liu
CZCen Zhang
Cen Zhang
WHWenwei Hu
Wenwei Hu
Zhaohui FengZhaohui Feng
Zhaohui Feng
P53 plays a key role in tumor suppression. The tumor suppressive function of p53 has long been attributed to its ability to induce apoptosis, cell cycle arrest, and senescence in cells. However, recent studies suggest that other functions of p53 also contribute to its role as a tumor suppressor, such as its function in metabolic regulation. p53 regulates various metabolic pathways to maintain the metabolic homeostasis of cells and adapt cells to stress. In addition, recent studies have also shown that gain-of-function (GOF) mutant p53 proteins drive metabolic reprogramming in cancer cells, contributing to cancer progression. Further understanding of p53 and its GOF mutants in metabolism will provide new opportunities for cancer therapy.

1 June 2017 in Journal of Molecular Biology
Verified
Journal Article
Closed access
XYXuetian Yue
Xuetian Yue
YZYuhan Zhao
Yuhan Zhao
YXYang Xu
Yang Xu
MZMin Zheng
Min Zheng
Zhaohui FengZhaohui Feng
Zhaohui Feng
WHWenwei Hu
Wenwei Hu

1 January 2015 in Cancer Letters
Verified
Journal Article
Closed access
JLJuan Liu
Juan Liu
CZCen Zhang
Cen Zhang
WHWenwei Hu
Wenwei Hu
Zhaohui FengZhaohui Feng
Zhaohui Feng

Verified
Journal Article
Open access
PDF file
JLJuan Liu
Juan Liu
CZCen Zhang
Cen Zhang
JWJianming Wang
Jianming Wang
WHWenwei Hu
Wenwei Hu
Zhaohui FengZhaohui Feng
Zhaohui Feng
Tumor suppressor p53 plays a key role in tumor suppression. In addition to tumor suppression, p53 is also involved in many other biological and pathological processes, such as immune response, maternal reproduction, tissue ischemia/reperfusion injuries and neurodegenerative diseases. While it has been widely accepted that the role of p53 in regulation of cell cycle arrest, senescence and apoptosis contributes greatly to the function of p53 in tumor suppression, emerging evidence has implicated that p53 also exerts its tumor suppressive function through regulation of many other cellular processes, such as metabolism, anti-oxidant defense and ferroptosis. Ferroptosis is a unique iron-dependent form of programmed cell death driven by lipid peroxidation in cells. Ferroptosis has been reported to be involved in cancer, tissue ischemia/reperfusion injuries and neurodegenerative diseases. Recent studies have shown that ferroptosis can be regulated by p53 and its signaling pathway as well as tumor-associated mutant p53. Interestingly, the regulation of ferroptosis by p53 appears to be highly context-dependent. In this review, we summarize recent advances in the regulation of ferroptosis by p53 and its signaling pathway. Further elucidation of the role and molecular mechanism of p53 in ferroptosis regulation will yield new therapeutic strategies for cancer and other diseases, including neurodegenerative diseases and tissue ischemia/reperfusion injuries.